Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 66Carcinoma, Renal Cell 38Liver Neoplasms 20Neoplasm Metastasis 17Carcinoma, Non-Small-Cell Lung 16Neoplasms 15Breast Neoplasms 15Melanoma 13Thyroid Neoplasms 10Leukemia, Myeloid, Acute 10Sarcoma 9Lung Neoplasms 8Kidney Neoplasms 8Prostatic Neoplasms 7Ovarian Neoplasms 7Urinary Bladder Neoplasms 6Pancreatic Neoplasms 6Glioblastoma 6Brain Neoplasms 6Colorectal Neoplasms 5Carcinoma, Medullary 5Thyroid Carcinoma, Anaplastic 4Stomach Neoplasms 4Rectal Neoplasms 4Gliosarcoma 4Gallbladder Neoplasms 4Colonic Neoplasms 4Breast Neoplasms, Male 4Thyroid Diseases 3Thyroid Cancer, Papillary 3

Interventions

Octreotide 3Capecitabine 3Temozolomide 2Everolimus 2Bortezomib 2vatalanib 1romidepsin 1regorafenib 1pazopanib 1pasireotide 1motesanib diphosphate 1fluorodopa F 18 1batifiban 1Thalidomide 1Streptozocin 1Sorafenib 1Solutions 1Saline Solution 1Panobinostat 1Melphalan 1Leucovorin 1Irinotecan 1Injections 1Gefitinib 1Fluorouracil 1Cisplatin 1Biological Therapy 1Bevacizumab 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Insulinoma × Sorafenib × Clear all
NCT00131911 2014-11-17

Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Completed
93 enrolled 10 charts
EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡